Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;89(3):434-44.
doi: 10.4269/ajtmh.13-0264.

Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years

Eduardo Gotuzzo  1 , Sergio Yactayo, Erika Córdova
Affiliations

Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years

Eduardo Gotuzzo et al. Am J Trop Med Hyg. 2013 Sep.

Abstract

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Eduardo Gotuzzo is an Advisory Board member and consultant for Pfizer and will participate in a study conducted by Sanofi Pasteur on the epidemiology of meningococcal infections.

Figures

Figure 1.
Figure 1.
Study selection flow diagram for vaccination against yellow fever (YF).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP. Informal WHO Working Group on Geographic Risk for Yellow Fever The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622–632. - PubMed
    1. Wilson ME, Chen LH, Barnett ED. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep. 2004;6:34–42. - PubMed
    1. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007;25:2758–2765. - PubMed
    1. Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2010;59:1–27. - PubMed
    1. Wilder-Smith A, Hill DR, Freedman DO. The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice. Am J Trop Med Hyg. 2008;78:359–360. - PubMed

Publication types

Substances